Why the study?
Does metformin prevent doxorubicin-induced cardiotoxicity in experimental models?
Does metformin prevent doxorubicin-induced cardiotoxicity in experimental models?
Metformin is a promising candidate for suppressing doxorubicin-induced cardiotoxicity in experimental models, warranting further clinical research.
Metformin may attenuate doxorubicin cardiotoxicity in experiments; leaves open clinical translation in oncology.
The article provides an overview of the currently known descriptions of the mechanisms and toxic effects of two drugs: doxorubicin, a first-line drug for the treatment of cancer, and the mechanisms of action of Metformin, a drug widely used for the treatment of diabetes mellitus 2. The review made with the usage of NCBI, PubMed and OxfordAcademic presents the analysis of published data on the protective effect of Metformin in its combined use with doxorubicin in an experiment in an attempt to reduce the manifestations of doxorubicin-induced cardiotoxicity.
No takes yet. Share an insight, caveat, or question.
Ionov et al. (2021) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: